Wire · operational-macro
Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In?
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 August 2026 · Fusion42 review
Regeneron Pharmaceuticals received FDA approval for Pasatru, a treatment for the rare disease fibrodysplasia ossificans progressiva, supported by late-stage OPTIMA trial data. Despite recent stock gains, the company's valuation is debated, with some models suggesting it is overvalued while discounted cash flow analysis indicates potential undervaluation.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 19 Aug 2026 and 22 Aug 2026.
◆ ◆ The Wire takeaway
New FDA approval opens a commercial door for you if you work in rare disease biotech, but valuation debates warn you to balance pipeline optimism with pricing and R&D risks.
◆ Coverage
2 sources · first reported 19 Aug 2026 · latest 22 Aug 2026
◆ Related on Wire
◆ Topics